Under the terms of the deal, ORPN will receive $3.5M, $1.5M upfront and $2.0M in a year, up to $17.0M in milestones plus royalties on net sales.
ORPN expects to finalize its merger with Enlivex Therapeutics Ltd. this quarter. It says current shareholders will have the opportunity to benefit from the success of Trehalose at Seelos via Contingent Value Rights (CVRs).
Trehalose, a protein stabilizing sugar molecule, is being developed to treat oculopharyngeal muscular dystrophy.
Subscribe for full text news in your inbox